Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic spontaneous urticaria
Biotech
Jasper warns of restructuring after dud drug derails trials
Jasper is blaming a dud batch of its urticaria drug for derailing a phase 1/2 study of the candidate and raising the possibility of a restructuring.
James Waldron
Jul 7, 2025 9:23am
Third Harmonic’s song to end as biotech looks to liquidate
Apr 14, 2025 9:01am
Novartis hands over $55M to license preclinical hives prospect
Mar 3, 2025 5:05pm
Third Harmonic halves headcount to take urticaria drug to ph. 2
Feb 11, 2025 7:58am
Allakos axes program, lays off 75% of staff after phase 1 flop
Jan 27, 2025 8:46am
Incyte's $750M buyout rocked by pause on key trial, asset cull
Nov 19, 2024 4:12am
